Milatuzumab, CAS 899796-83-9

Product Description: Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Alinari L, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41.

CAS Number: 899796-83-9

Molecular Weight: N/A

Compound Purity: 99.39

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: CD74

• SKU: MEXHY-P99731-1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P99731-1
• Package Unit: 1 mg
• Quantity Unit: STK
• Conjugate: Unconjugated